{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:32:13Z","timestamp":1772181133543,"version":"3.50.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>IL-15 has shown preclinical activity by enhancing the functional maturation of natural killer (NK) cells. Clinical evaluation of the potential anticancer activity of most cytokines, including IL-15, has been limited by low tolerability and rapid <jats:italic>in vivo<\/jats:italic> clearance. Efbalropendekin Alfa (XmAb24306) is a soluble IL15\/IL15-receptor alpha heterodimer complex fused to a half-life extended Fc domain (IL15\/IL15R\u03b1-Fc), engineered with mutations to reduce IL-15 affinity for CD122. Reduced affinity drives lower potency, leading to prolonged pharmacodynamic response in cynomolgus monkeys. We show that <jats:italic>in vitro<\/jats:italic>, human NK cells treated with XmAb24306 demonstrate enhanced cytotoxicity against various tumor cell lines. XmAb24306-treated NK cells also exhibit enhanced killing of 3D colorectal cancer spheroids. Daratumumab (dara), a monoclonal antibody (mAb) that targets CD38 results in antibody-dependent cellular cytotoxicity (ADCC) of both multiple myeloma (MM) cells and NK cells. Addition of XmAb24306 increases dara-mediated NK cell ADCC against various MM cell lines <jats:italic>in vitro<\/jats:italic>. Because NK cells express CD38, XmAb24306 increases dara-mediated NK cell fratricide, but overall does not negatively impact the ADCC activity against a MM cell line likely due to increased NK cell activity of the surviving cells. These data show that XmAb24306 increases direct and ADCC-mediated human NK cell cytotoxicity <jats:italic>in vitro<\/jats:italic>.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1341804","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T04:44:12Z","timestamp":1709786652000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Efbalropendekin Alfa enhances human natural killer cell cytotoxicity against tumor cell lines in vitro"],"prefix":"10.3389","volume":"15","author":[{"given":"Hesham M.","family":"Shehata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranay","family":"Dogra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Gierke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Holder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shomyseh","family":"Sanjabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00746-x","article-title":"Strategies to therapeutically modulate cytokine action","volume":"22","author":"Leonard","year":"2023","journal-title":"Nat Rev Drug Discovery"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br J Cancer"},{"key":"B4","article-title":"High-dose aldesleukin in renal cell carcinoma: long-term survival update","author":"Fisher","year":"1997","journal-title":"Cancer J Sci Am"},{"key":"B5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J Immunother Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1089\/jir.2018.0019","article-title":"Cytokines in the treatment of cancer","volume":"39","author":"Conlon","year":"2019","journal-title":"J Interferon Cytokine Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0945","article-title":"Phase I trial of ALT-803, A novel recombinant IL15 complex, in patients with advanced solid tumors","volume":"24","author":"Margolin","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2451","article-title":"A first-in-human phase I study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors","volume":"24","author":"Miller","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00868","article-title":"IL-15 in the combination immunotherapy of cancer","volume":"11","author":"Waldmann","year":"2020","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"114112","DOI":"10.1016\/j.addr.2022.114112","article-title":"Engineering interferons and interleukins for cancer immunotherapy","volume":"182","author":"Holder","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1003222","DOI":"10.1371\/journal.pcbi.1003222","article-title":"Mechanistic model of natural killer cell proliferative response to IL-15 receptor stimulation","volume":"9","author":"Zhao","year":"2013","journal-title":"PloS Comput Biol"},{"key":"B14","author":"Bernett","year":"2018","journal-title":"Cancer Res"},{"key":"B15","volume-title":"Society for Immunotherapy of Cancer Annual Meeting (poster)","author":"Bernett","year":"2018"},{"key":"B16","doi-asserted-by":"publisher","first-page":"106450","DOI":"10.1016\/j.ejps.2023.106450","article-title":"Complex PK-PD of an engineered IL-15\/IL-15Ralpha-Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics","volume":"186","author":"Lu","year":"2023","journal-title":"Eur J Pharm Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0272-z","article-title":"The cancer-natural killer cell immunity cycle","volume":"20","author":"Huntington","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","article-title":"Tumor-infiltrating natural killer cells","volume":"11","author":"Cozar","year":"2021","journal-title":"Cancer Discovery"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101988","article-title":"Immune surveillance properties of human NK cell-derived exosomes","volume":"189","author":"Lugini","year":"2012","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20181454","article-title":"NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing","volume":"216","author":"Prager","year":"2019","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118726","article-title":"Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-derived cytokines","volume":"97","author":"Bluman","year":"1996","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-238469","article-title":"Regulation of human NK-cell cytokine and chemokine production by target cell recognition","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2429","article-title":"Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells","volume":"66","author":"Roda","year":"2006","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41392-020-00348-8","article-title":"Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy","volume":"5","author":"Cao","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.136.12.4480","article-title":"The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes","volume":"136","author":"Lanier","year":"1986","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1600-065X.2006.00457.x","article-title":"Activation, coactivation, and costimulation of resting human natural killer cells","volume":"214","author":"Bryceson","year":"2006","journal-title":"Immunol Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1189\/jlb.5VMR0415-141R","article-title":"Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions","volume":"99","author":"Battella","year":"2016","journal-title":"J Leukoc Biol"},{"key":"B29","article-title":"Receptors for the Fc fragment of IgG on natural killer cells","volume":"12","author":"Trinchieri","year":"1993","journal-title":"Nat Immun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00368","article-title":"NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1822","article-title":"From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention","volume":"17","author":"Landgren","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-02-895193","article-title":"A phase 1b study of isatuximab plus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma","volume":"134","author":"Mikhael","year":"2019","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121522","article-title":"Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab","volume":"8","author":"Martin","year":"2019","journal-title":"Cells"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B43","first-page":"75","article-title":"Protection against natural killer cells by interferon-gamma treatment of K562 cells cannot be explained by augmented major histocompatibility complex class I expression","volume":"83","author":"Nishimura","year":"1994","journal-title":"Immunology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/jnci\/59.1.77","article-title":"Specificity of natural cytotoxic reactivity of normal human lymphocytes against a myeloid leukemia cell line","volume":"59","author":"Ortaldo","year":"1977","journal-title":"J Natl Cancer Inst"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3418","article-title":"Adaptive natural killer cells facilitate effector functions of daratumumab in multiple myeloma","volume":"27","author":"Cho","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B46","article-title":"An improved flow cytometry-based natural killer cytotoxicity assay involving calcein AM staining of effector cells","volume":"42","author":"Jang","year":"2012","journal-title":"Ann Clin Lab Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20122292","article-title":"Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRgamma activation","volume":"210","author":"Leung","year":"2013","journal-title":"J Exp Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0587-5","article-title":"DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma","volume":"34","author":"Choudhry","year":"2020","journal-title":"Leukemia"},{"key":"B49","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41408-018-0168-2","article-title":"Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6\/PLD-1","volume":"9","author":"Ernst","year":"2019","journal-title":"Blood Cancer J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1486948","article-title":"Daratumumab induces CD38 internalization and impairs myeloma cell adhesion","volume":"7","author":"Ghose","year":"2018","journal-title":"Oncoimmunology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","article-title":"NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma","volume":"11","author":"Leivas","year":"2021","journal-title":"Blood Cancer J"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2140-1","article-title":"Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions","volume":"67","author":"Mahaweni","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1694-4","article-title":"Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A","volume":"64","author":"Sarkar","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00604.x","article-title":"Twelve immunotherapy drugs that could cure cancers","volume":"222","author":"Cheever","year":"2008","journal-title":"Immunol Rev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1084\/jem.20082013","article-title":"IL-15 trans-presentation promotes human NK cell development and differentiation","volume":"206","author":"Huntington","year":"2009","journal-title":"vivo. J Exp Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133103","article-title":"Discovery of specialized NK cell populations infiltrating human melanoma metastases","volume":"4","author":"de Andrade","year":"2019","journal-title":"JCI Insight"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3190","article-title":"CD38-targeted immunochemotherapy in refractory multiple myeloma: A new horizon","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2040620719894871","DOI":"10.1177\/2040620719894871","article-title":"Daratumumab in untreated newly diagnosed multiple myeloma","volume":"10","author":"Abdallah","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000734","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma","volume":"8","author":"Shah","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1341804\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T04:44:33Z","timestamp":1709786673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1341804\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2024.1341804"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1341804","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"article-number":"1341804"}}